On this page
Polymyxin B Sulfate and Trimethoprim
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Cytochrome P450 2C8 Inhibitors [MoA] | MoA | All 56 members |
| Dihydrofolate Reductase Inhibitor Antibacterial [EPC] | EPC | 8 members — no class page |
| Dihydrofolate Reductase Inhibitors [MoA] | MoA | All 25 members |
| Organic Cation Transporter 2 Inhibitors [MoA] | MoA | All 32 members |
| Polymyxin-class Antibacterial [EPC] | EPC | All 55 members |
| Polymyxins [CS] | CS | All 55 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 064211-001 | TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE | SOLUTION/DROPS | POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE | Prescription | AT | RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 16 | Labeling | Approved | May 18, 2020 | Standard |
| Supplement | 9 | Manufacturing (CMC) | Approved | December 23, 2002 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | October 1, 2002 | — |
| Supplement | 7 | Labeling | Approved | June 13, 2002 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | April 19, 2002 | — |
| Supplement | 5 | Labeling | Approved | October 5, 2001 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | August 15, 2000 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | April 7, 2000 | — |
| Supplement | 1 | Labeling | Approved | November 29, 1999 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | October 26, 1999 | — |
| Original application | 1 | Approved | April 13, 1998 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260127). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenzae and Pseudomonas aeruginosa. * *Efficacy for this organism in this organ system was studied in fewer than 10 infections.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION In mild to moderate infections, instill one drop in the affected eye(s) every three hours (maximum of 6 doses per day) for a period of 7 to 10 days.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is contraindicated in patients with known hypersensitivity to any of its components.
Warnings
openFDA Drug LabelingWARNINGS NOT FOR INJECTION INTO THE EYE. If a hypersensitivity reaction to Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution occurs, discontinue use. Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is not indicated for the prophylaxis or treatment of ophthalmia neonatorum.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The most frequent adverse reaction to Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is local irritation consisting of increased redness, burning, stinging, and/or itching. This may occur on instillation, within 48 hours, or at any time with extended use. There are also multiple reports of hypersensitivity reactions consisting of lid edema, itching, increased redness, tearing, and/or circumocular rash. Stevens- Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and anaphylaxis have been reported. Photosensitivity has been reported in patients taking oral trimethoprim. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is a sterile antimicrobial solution for topical ophthalmic use. It has a pH of 4.0 to 6.2 and osmolality of 270 to 310 mOsm/kg. Chemical Names: Trimethoprim sulfate, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine sulfate (2:1), is a white, odorless, crystalline powder with a molecular weight of 678.72 and the following structural formula: Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formula are: Contains: Actives: polymyxin B sulfate 10,000 units/mL; trimethoprim sulfate equivalent to trimethoprim 1mg/mL. Preservative: benzalkonium chloride 0.04 mg/mL. Inactives: sodium chloride; sulfuric acid and purified water. May also contain sodium hydroxide for pH adjustment. trimethoprim-chemical polymyxin-chemical polymyxin-text
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution, USP is a sterile solution. Each mL contains trimethoprim sulfate equivalent to 1 mg trimethoprim and polymyxin B sulfate 10,000 units in NDC: 70518-1735-00 PACKAGING: 10 mL in 1 BOTTLE PLASTIC TYPE 0 Storage: Store at 15° to 25°C (59° to 77°F) and protect from light. Repackaged and Distributed By: Remedy Repack, Inc. 625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: POLYMYXIN B SULFATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-2925-0 | 50090-2925 | A-S Medication Solutions | 10 mL in 1 BOTTLE, PLASTIC (50090-2925-0) | March 16, 2017 |
| 68071-4103-5 | 68071-4103 | NuCare Pharmaceuticals,Inc. | 10 mL in 1 BOX (68071-4103-5) | December 22, 2017 |
| 68788-6927-1 | 68788-6927 | Preferred Pharmacetucials Inc. | 10 mL in 1 BOTTLE, PLASTIC (68788-6927-1) | March 30, 2018 |
| 63187-834-10 | 63187-834 | Proficient Rx LP | 10 mL in 1 BOTTLE, PLASTIC (63187-834-10) | December 1, 2018 |
| 70518-1735-0 | 70518-1735 | REMEDYREPACK INC. | 10 mL in 1 BOTTLE, PLASTIC (70518-1735-0) | December 14, 2018 |
| 61314-628-10 | 61314-628 | Sandoz Inc | 1 BOTTLE, PLASTIC in 1 CARTON (61314-628-10) / 10 mL in 1 BOTTLE, PLASTIC | April 16, 1998 |
| 50090-2925 | 50090-2925 | A-S Medication Solutions | — | April 16, 1998 |
| 68071-4103 | 68071-4103 | NuCare Pharmaceuticals,Inc. | — | April 16, 1998 |
| 68788-6927 | 68788-6927 | Preferred Pharmacetucials Inc. | — | March 30, 2018 |
| 63187-834 | 63187-834 | Proficient Rx LP | — | April 16, 1998 |
| 70518-1735 | 70518-1735 | REMEDYREPACK INC. | — | December 14, 2018 |
| 61314-628 | 61314-628 | Sandoz Inc | — | April 16, 1998 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.